Matricelf is a biotechnology company in the field of tissue engineering.
The company develops a platform for autologous (personal) 3D printing of tissues and organs that significantly reduce the risk of implant rejection.
Using a single biopsy from the patient we develop tissues (cells and scaffold) that we can 3D print, inject or simply place where needed.
In 2019, we printed, for the first time in human history, a three-dimensional human heart from human tissue.
Matricelf’s technology aims to completely regenerate the future of medicine.
The company completed successful pre-clinical studies in a number of
medical conditions such as acute Myocardial Infarction, Parkinson’s Disease, Age related Macular Degeneration and more.
Our first indication is Spinal Cord Injury.
Each year, there are tens of thousands of new cases of traumatic Spinal Cord Injuries that usually lead to paralysis.
Considering the fact that SCI patients have no suggested treatments and are expected to spend their life in a wheelchair motivated us to further develop the technology and specifically SCI implant.
In our pre-clinical animal studies, mice treated with our implants regained their walking ability both in acute and chronic spinal cord injury models.